NEJM: Atezolizumab Combines Beva mono-resistant treatment for non-reprecision liver cancer
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
In Phase I clinical, Atezolizumab's combination of bevala monoantigens showed good therapeutic results in patients with non-resectionable hepatocellular carcinomarecently researchers conducted Phase III clinical studies, previously not subjected to systemic treatment of non-recectorable hepatocellular carcinoma patients randomly accepted atezolizumab combined with bevaparm or sorafeniThe end of the study was the overall survival rate and non-progression survival rate in the intended treatment population336 patients in the Atezolizumab-Bevado monoantigen group and 165 patients in the Sorafini groupAt the time of preliminary analysis (29 August 2019), atezolizumab-bevali had a risk-of-death ratio of 0.58 compared to the Sorafeni groupThe total survival rate for 12 months in the Atezolizumab-Bevalmono group was 67.2 per cent, in the Sorafii group was 54.6 per cent, and the median non-progressive survival was 6.8 months and 4.3 months, respectively (risk ratio of disease progression or death: 0.59)329 patients experienced stage III or stage 4 adverse events, 56.5 per cent received at least one dose of Atezolizumab-belav, and 55.1 per cent received at least one dose of sorofaniIn the Atezolizumab-beval monoantigen group, 15.2% of patients had level 3 or 4 hypertensionstudies suggest that Atezolizumab's combination of bevadoresistance can significantly prolong the survival of patients with non-rectoctable liver cancer compared to Sorafini
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
